Loading...
•
Sep 30, 2024
Collegium Q3 2024 Earnings Report
Collegium reported record Q3 2024 financial results.
Key Takeaways
Collegium announced record third-quarter net revenue of $159.3 million, a 17% increase year-over-year. This growth was driven by record revenues from Belbuca and Xtampza ER. The company reported a GAAP net income of $9.3 million and an adjusted EBITDA of $105.1 million, also up 18% year-over-year. Collegium also completed the acquisition of Ironshore Therapeutics, marking its entry into neurology.
Generated record Q3 2024 net revenue of $159.3 million, up 17% year-over-year.
Belbuca revenue reached a record $53.2 million, and Xtampza ER revenue also hit a record at $49.5 million.
Achieved Q3 2024 GAAP net income of $9.3 million.
Closed acquisition of Ironshore Therapeutics, establishing a presence in neurology (ADHD).
Revenue by Segment
Forward Guidance
The Company reaffirms its full-year 2024 guidance as updated in September 2024 following the close of the Ironshore acquisition for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA for its current business.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...